[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 354,003
  • Shares Outstanding, K 249,298
  • Annual Sales, $ 14,560 K
  • Annual Income, $ -63,530 K
  • EBIT $ -22 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.60
  • Price/Sales 26.20
  • Price/Cash Flow N/A
  • Price/Book 8.02

Options Overview Details

View History
  • Implied Volatility 154.65% (+47.06%)
  • Historical Volatility 50.83%
  • IV Percentile 46%
  • IV Rank 17.23%
  • IV High 516.69% on 06/12/25
  • IV Low 79.27% on 04/21/26
  • Expected Move (DTE 10) 0.1870 (13.17%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 1,011
  • Volume Avg (30-Day) 342
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 11,238
  • Open Int (30-Day) 9,001
  • Expected Range 1.2330 to 1.6070

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.02
  • Number of Estimates 2
  • High Estimate $-0.01
  • Low Estimate $-0.03
  • Prior Year $-0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4000 +1.43%
on 05/04/26
1.7500 -18.86%
on 04/17/26
-0.1500 (-9.55%)
since 04/02/26
3-Month
1.4000 +1.43%
on 05/04/26
1.9850 -28.46%
on 03/02/26
-0.3200 (-18.39%)
since 02/04/26
52-Week
0.4250 +234.12%
on 05/07/25
2.0900 -32.06%
on 11/03/25
+0.9293 (+189.38%)
since 05/02/25

Most Recent Stories

More News
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Gains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy (GA) lesion site ...

LCTX : 1.4200 (-7.19%)
Lineage Announces Formation of Scientific Advisory Board

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...

LCTX : 1.4200 (-7.19%)
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD)...

LCTX : 1.4200 (-7.19%)
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen ® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 ...

LCTX : 1.4200 (-7.19%)
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...

LCTX : 1.4200 (-7.19%)
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions,...

LCTX : 1.4200 (-7.19%)
Lineage Cell Therapeutics Issues Letter to Stockholders

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions,...

LCTX : 1.4200 (-7.19%)
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen ® ) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 ...

LCTX : 1.4200 (-7.19%)
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...

LCTX : 1.4200 (-7.19%)
Anti-Aging Market Surges as $101M Competition Drives Demographic Revolution

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The global longevity biotech market exploded from $27.15 billion in 2024 toward $46.61 billion by 2033...

LXRX : 1.6000 (-1.84%)
AVAI : 0.3500 (+6.90%)
LCTX : 1.4200 (-7.19%)
ARQT : 23.49 (+0.60%)
AMGN : 323.85 (-1.81%)

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 1.6067
2nd Resistance Point 1.5613
1st Resistance Point 1.4907
Last Price 1.4200
1st Support Level 1.3747
2nd Support Level 1.3293
3rd Support Level 1.2587

See More

52-Week High 2.0900
Fibonacci 61.8% 1.4540
Last Price 1.4200
Fibonacci 50% 1.2575
Fibonacci 38.2% 1.0610
52-Week Low 0.4250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.